These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 27868150)
61. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678 [TBL] [Abstract][Full Text] [Related]
62. A betamethasone-calcipotriene combination for psoriasis. Med Lett Drugs Ther; 2006 Jul; 48(1238):55-6. PubMed ID: 16841023 [TBL] [Abstract][Full Text] [Related]
63. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761 [TBL] [Abstract][Full Text] [Related]
64. Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis. Xu X; Davelaar N; Mus AM; Asmawidjaja PS; Hazes JMW; Baeten DLP; Vis M; Bisoendial RJ; Prens EP; Lubberts E Arthritis Rheumatol; 2020 Aug; 72(8):1303-1313. PubMed ID: 32243724 [TBL] [Abstract][Full Text] [Related]
65. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. Schaper K; Dickhaut J; Japtok L; Kietzmann M; Mischke R; Kleuser B; Bäumer W J Dermatol Sci; 2013 Jul; 71(1):29-36. PubMed ID: 23643308 [TBL] [Abstract][Full Text] [Related]
66. Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study. Toole JW Skin Therapy Lett; 2007 May; 12(4):1-3. PubMed ID: 17551662 [TBL] [Abstract][Full Text] [Related]
67. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol). Guenther LC Skin Therapy Lett; 2009 May; 14(4):1-4. PubMed ID: 19585059 [TBL] [Abstract][Full Text] [Related]
68. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Kin KC; Hill D; Feldman SR Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906 [TBL] [Abstract][Full Text] [Related]
69. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. Reichrath J; Müller SM; Kerber A; Baum HP; Bahmer FA J Am Acad Dermatol; 1997 Jan; 36(1):19-28. PubMed ID: 8996256 [TBL] [Abstract][Full Text] [Related]
70. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. van Geel MJ; Mul K; Oostveen AM; van de Kerkhof PC; de Jong EM; Seyger MM Br J Dermatol; 2014 Aug; 171(2):363-9. PubMed ID: 24593129 [TBL] [Abstract][Full Text] [Related]
71. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model. Sun J; Dou W; Zhao Y; Hu J Immunopharmacol Immunotoxicol; 2014 Feb; 36(1):17-24. PubMed ID: 24286371 [TBL] [Abstract][Full Text] [Related]
72. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. van de Kerkhof PC; Hoffmann V; Anstey A; Barnes L; Bolduc C; Reich K; Saari S; Segaert S; Vaillant L Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709 [TBL] [Abstract][Full Text] [Related]
73. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Kragballe K; Noerrelund KL; Lui H; Ortonne JP; Wozel G; Uurasmaa T; Fleming C; Estebaranz JL; Hanssen LI; Persson LM Br J Dermatol; 2004 Jun; 150(6):1167-73. PubMed ID: 15214905 [TBL] [Abstract][Full Text] [Related]
74. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. Lambert J; Hol CW; Vink J J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069 [TBL] [Abstract][Full Text] [Related]
75. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Ortonne JP; Kaufmann R; Lecha M; Goodfield M Dermatology; 2004; 209(4):308-13. PubMed ID: 15539894 [TBL] [Abstract][Full Text] [Related]
76. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Traulsen J; Hughes-Formella BJ Dermatology; 2003; 207(2):166-72. PubMed ID: 12920367 [TBL] [Abstract][Full Text] [Related]
77. Psoriatic Erythroderma Caused by Terbinafine: A Possible Pathogenetic Role for IL-23. Oda T; Sawada Y; Yamaguchi T; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Okada E; Nakamura M J Investig Allergol Clin Immunol; 2017; 27(1):63-64. PubMed ID: 28211348 [No Abstract] [Full Text] [Related]
78. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Peeters P; Ortonne JP; Sitbon R; Guignard E Dermatology; 2005; 211(2):139-45. PubMed ID: 16088161 [TBL] [Abstract][Full Text] [Related]
79. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981 [TBL] [Abstract][Full Text] [Related]
80. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Rigopoulos D; Gregoriou S; Daniel Iii CR; Belyayeva H; Larios G; Verra P; Stamou C; Kontochristopoulos G; Avgerinou G; Katsambas A Dermatology; 2009; 218(4):338-41. PubMed ID: 19212110 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]